|
|
|
|
|
|
|
Study 2B
|
|
Study 1
|
Study 2A
|
First 4-h Monitoring
|
Second 4-h Monitoring
|
|
Placebo (n = 44) |
Sildenafil (n = 44) |
P* Value |
Placebo (n = 25) |
Sildenafil (n = 25) |
P* Value |
Placebo (n = 25) |
Sildenafil (n = 25) |
P* Value |
Placebo (n = 25) |
Sildenafil (n = 25) |
P* Value |
|
| No. of valid erections |
1.73 (0.13) |
2.09 (0.15) |
.025 |
3.12 (0.26) |
4.44 (0.29) |
.000 |
1.56 (0.13) |
2.12 (0.18) |
.008 |
1.6 (0.19) |
2.44 (0.18) |
.000 |
Total duration of rigidity  70% (minutes) |
28.09 (3.71) |
44.81 (4.90) |
.000 |
70.10 (8.02) |
117.98 (10.82) |
.000 |
31.96 (5.26) |
45.11 (6.68) |
.005 |
37.73 (5.47) |
72.85 (6.42) |
.000 |
| Total duration of increase of tumescence 30 mm (minutes) |
25.09 (2.79) |
43.71 (4.40) |
.000 |
51.67 (6.76) |
107.50 (11.20) |
.000 |
23.17 (3.76) |
42.67 (5.64) |
.000 |
28.78 (4.32) |
66.52 (6.88) |
.000 |
| Maximum rigidity (%) |
80.57 (3.34) |
87.04 (2.39) |
.017 |
89.82 (1.92) |
93.34 (0.37) |
.016 |
83.54 (4.03) |
89.19 (1.68) |
.140 |
86.9 (2.4) |
92.82 (1.37) |
.007 |
| Mean of maximum rigidity (%) |
73.07 (3.15) |
80.48 (2.35) |
.004 |
80.86 (2.30) |
85.42 (1.79) |
.010 |
76.50 (3.99) |
83.19 (1.89) |
.08 |
82.23 (2.62) |
87.80 (2.00) |
.026 |
| Maximum increase of tumescence (mm) |
38.73 (1.94) |
40.47 (1.56) |
.125 |
40.24 (1.55) |
43.48 (1.61) |
.010 |
37.76 (2.08) |
40.67 (1.71) |
.038 |
38.36 (1.72) |
43.28 (1.60) |
.002 |
|
| *P value derived from Student's t test for paired
data. The comparisons were considered significant when P <.05. |
